Clinical Trial Update: Adjuvant Tebentafusp in High Risk Ocular Melanoma [Phase 3]

View source ↗

Summary

This update notes ongoing Phase 3 recruitment for adjuvant tebentafusp in high-risk uveal melanoma, sponsored by the European Organisation for Research and Trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• KIMMTRI (tebentafusp)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Uveal Melanoma | Phase 3 | Status: RECRUITING